Advertisement

Pediatric Rheumatology

, 12:P150 | Cite as

Cardiopulmonary involvement in juvenile systemic sclerosis: development of recommendations for screening and investigation

  • Clare Pain
  • Tamas Constantin
  • Eileen Baildam
  • Christian Beyer
  • Henning Lenhartz
  • Michael Blakley
  • Dana Nemcova
  • Clarissa Pilkington
  • Ivan Foeldvari
  • PRES Scleroderma Working group
  • PRES Scleroderma Working Group
Open Access
Poster presentation

Keywords

Scleroderma Consensus Expert Paediatric Cardiologist Adult Study Aggressive Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

BP

blood pressure

ECG

electrocardiogram

ECHO

echocardiogram

MRI

magnetic resonance imaging

HRCT

high resolution computerised tomography

PFT DLCO

pulmonary function tests with diffusion capacity of lung for carbon monoxide

6MWT

6 minute walk test

Introduction

There are currently no agreed recommendations on how to investigate children for cardiopulmonary involvement in Juvenile Systemic Sclerosis (JSSc). The aim of screening is to detect disease early to facilitate early aggressive therapy and improve outcomes. Cardiopulmonary involvement is the leading cause of death in JSSc and cardiopulmonary at diagnosis incurs a worse outcome [1]. Most deaths occur early in the disease course [1, 2].

Objectives

To develop recommendations for investigation of cardiopulmonary in JSSc, based on paediatric evidence and where this was lacking, consensus expert agreement.

Methods

Members of the PRES Scleroderma Working Group were invited to participate; additionally a paediatric cardiologist was invited. A nominal group technique was used. 75% consensus was defined as agreement.

Results

Table 1 shows the recommendations for screening for cardiopulmonary at baseline and at defined time points from diagnosis. Other recommendations agreed by the group which are relevant at any stage in the disease course are as follows (in Table 1).
Table 1

Recommendations for screening for cardiopulmonary involvement in JSSc at baseline and follow-up (75% consensus defined as agreement)

Cardiopulmonary

Baseline

 

All patients should undergo:

- BP

- 12 lead ECG

- 24 hour ECG

- ECHO with Doppler

- Cardiac MRI with gadolinium

- HRCT thorax

- PFT with DLCO

- 6MWT

 

Follow-up screening (for first 5 years from diagnosis)*

 

6 monthly

12 lead ECG

ECHO with doppler

6MWT

PFT with DLCO

 

Annual

24hr ECG

 

At 3 years

Repeat HRCT

*screening guidelines are based on asymptomatic patients. However, children may need more frequent monitoring depending on clinical status and abnormalities detected on previous investigation.

Recommendations are based on low grade evidence and in the most part from expert consensus opinion with extrapolation from adult studies.

Conclusion

JSSc has a significant mortality particularly early on in the disease course. The objective of an aggressive screening program is to identify cardiopulmonary involvement at a stage which may be amenable to treatment. The recommendations developed by this group aim to standardise care and improve outcomes in this rare disease.

Disclosure of interest

None declared

Copyright information

© Pain et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Clare Pain
    • 1
  • Tamas Constantin
    • 2
  • Eileen Baildam
    • 3
  • Christian Beyer
    • 4
  • Henning Lenhartz
    • 5
  • Michael Blakley
    • 6
  • Dana Nemcova
    • 7
  • Clarissa Pilkington
    • 8
  • Ivan Foeldvari
    • 9
  • PRES Scleroderma Working group
  • PRES Scleroderma Working Group
  1. 1.Pediatric RheumatologyLiverpoolUK
  2. 2.Pediatric RheumatologyBudapestHungary
  3. 3.Pediatric RheumatologsLiverpoolUK
  4. 4.Pediatric CardiologyHamburgGermany
  5. 5.Pediatric GastroenterologyHamburgGermany
  6. 6.Pediatric RheumatologyIndianaUSA
  7. 7.Pediatirc RheumatologyPragueCzech Republic
  8. 8.Pediatric RheumatologyLondonUK
  9. 9.Hamburger Zentrum für KinderrheumatologieHamburgGermany

Personalised recommendations